Recent studies have demonstrated that blocking MYC function may be sufficient to stop tumor growth and induce tumor regression in the well-characterized LSL KRAS G12D mouse models of NSCLC and PDAC [45, 46, 47]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.